GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Goodwill-to-Asset

BRAIN Biotech AG (XTER:BNN) Goodwill-to-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. BRAIN Biotech AG's Goodwill for the quarter that ended in Mar. 2024 was €0.00 Mil. BRAIN Biotech AG's Total Assets for the quarter that ended in Mar. 2024 was €73.25 Mil. Therefore, BRAIN Biotech AG's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 was 0.00.


BRAIN Biotech AG Goodwill-to-Asset Historical Data

The historical data trend for BRAIN Biotech AG's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Goodwill-to-Asset Chart

BRAIN Biotech AG Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only 0.07 0.06 0.06 0.09 0.09

BRAIN Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.09 - -

Competitive Comparison of BRAIN Biotech AG's Goodwill-to-Asset

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG's Goodwill-to-Asset Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Goodwill-to-Asset falls into.



BRAIN Biotech AG Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

BRAIN Biotech AG's Goodwill to Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Goodwill to Asset (A: Sep. 2023 )=Goodwill/Total Assets
=6.67/70.937
=0.09

BRAIN Biotech AG's Goodwill to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Goodwill to Asset (Q: Mar. 2024 )=Goodwill/Total Assets
=0/73.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BRAIN Biotech AG  (XTER:BNN) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


BRAIN Biotech AG Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BRAIN Biotech AG (XTER:BNN) Business Description

Traded in Other Exchanges
Address
Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Executives
Dr. Michael Majerus Supervisory Board
Dr. Georg Kellinghusen Supervisory Board
Michael Schneiders Board of Directors
Adriaan Moelker Board of Directors
Lukas Linnig Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines